Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting
Valérie Dutoit, … , Lloyd J. Old, Danila Valmori
Valérie Dutoit, … , Lloyd J. Old, Danila Valmori
Published December 15, 2002
Citation Information: J Clin Invest. 2002;110(12):1813-1822. https://doi.org/10.1172/JCI16428.
View: Text | PDF
Article Immunology

Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting

  • Text
  • PDF
Abstract

Research Article

Authors

Valérie Dutoit, Robert N. Taub, Kyriakos P. Papadopoulos, Susan Talbot, Mary-Louise Keohan, Michelle Brehm, Sacha Gnjatic, Paul E. Harris, Brygida Bisikirska, Philippe Guillaume, Jean-Charles Cerottini, Charles S. Hesdorffer, Lloyd J. Old, Danila Valmori

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Fine specificity of antigen recognition and tumor reactivity of distinct...
Fine specificity of antigen recognition and tumor reactivity of distinct NY-ESO-1 multimer+ CTL recognizing overlapping epitopes in the 157-167 region. (a) Recognition of NY-ESO-1 peptides by polyclonal monospecific multimer+–sorted populations as well as by the NY-ESO-1–specific tumor-reactive clone LAU 156/5 used as an internal control was assessed in a 51Cr release assay on T2 target cells in the presence of graded concentration of the indicated peptides. (b) Tumor recognition was similarly assessed on Me 275 (A2+ NY-ESO-1+) or Me 260 (A2–) tumor target cells at the indicated E/T ratio.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts